Lennox-Gastaut Syndrome Workup

  • Author: Koshi A Cherian, MD; Chief Editor: Amy Kao, MD   more...
 
Updated: Jan 26, 2012
 

Approach Considerations

Electroencephalography (EEG) is an essential part of the workup for Lennox-Gastaut syndrome (LGS). To date, there are no known laboratory investigations to aid in the diagnosis of LGS. Neuroimaging is an important part of the search for an underlying etiology in a patient with LGS.

Next

Electroencephalography

Always perform an EEG in patients with suspected LGS, since the diagnosis depends on the presence of specific EEG findings. A routine 20-minute EEG may not capture the patient both awake and asleep and thus may miss specific important EEG findings. Instead, obtain prolonged video/EEG telemetry, if possible. Record both waking and sleep EEG, to assist in confirming a suspected diagnosis and to capture and classify each of the patient's multiple seizure types.

Video recordings can also be used to educate the parents on which of the patient's "events" are seizures and which are nonepileptic behavioral events. Parental ability to correctly recognize and identify atypical absences is poor. In one study using video/EEG monitoring in a cohort of children with LGS, parental recognition was 27% for atypical absences, while the sensitivity was as high as 80% for myoclonic seizures and 100% for tonic, atonic, tonic-clonic, clonic, and complex partial seizures.[7]

Go to EEG in Common Epilepsy Syndromes, Epileptiform Normal Variants on EEG, and Generalized Epilepsies on EEG for more information on these topics.

Interictal electroencephalography

Interictal EEG is characterized by a slow background that can be constant or transient. Permanent slowing of the background is associated with poor cognitive prognosis.

The hallmark of the awake interictal EEG in patients with LGS is the diffuse slow spike wave (see the image below). This pattern consists of bursts of irregular and generalized spikes or sharp waves followed by a sinusoidal 35-400-millisecond slow wave with an amplitude of 200-800 microvolts, which can be symmetric or asymmetric.

The amplitude often is higher in the anterior region or in the frontal or frontocentral areas, but in some patients the activity may dominate in the posterior head regions. The frequency of the slow spike wave activity commonly is found at 1.5-2.5 Hz.

Slow spike wave pattern in a 24-year-old awake malSlow spike wave pattern in a 24-year-old awake male with Lennox-Gastaut syndrome. The slow posterior background rhythm has frequent periods of 2- to 2.5-Hz discharges, maximal in the bifrontocentral areas, occurring in trains as long as 8 seconds without any clinical accompaniment.

Slow spike waves usually are not activated by photic stimulation. Hyperventilation rarely induces slow spike waves, although mental retardation prevents adequate cooperation in many patients. During non–rapid eye movement (REM) sleep, discharges are more generalized, more frequent, and consist of polyspikes and slow waves. In REM sleep, spike waves decrease. During periods of frequent seizures, the total duration of REM sleep is reduced.

Ictal electroencephalography

During a tonic seizure, the EEG is characterized by a diffuse, rapid (10-13 Hz), low-amplitude activity pattern, mainly in the anterior and vertex areas ("recruiting rhythm") that progressively decreases in frequency and increases in amplitude.

A brief generalized discharge of slow spike waves or flattening of the recording may precede this pattern. Diffuse slow waves and slow spike waves may follow it.

These fast discharges are common during non-REM sleep. Unlike tonic-clonic seizures, no postictal flattening occurs with these seizures. Clinical manifestations appear 0.5-1 second after the onset of EEG manifestations and last several seconds longer than the discharge.

During an atypical absence seizure, the EEG is characterized by diffuse, slow (2-2.5 Hz), and irregular spike waves, which may be difficult to differentiate from interictal bursts. Occasionally, discharges of rapid rhythms may be observed preceded by flattening of the record for 1-2 seconds, followed by progressive development of irregular fast rhythm in the anterior and central regions, and ending with brief spike waves.

During atonic, massive myoclonic, and myoclonic-atonic seizures, the EEG is characterized by slow spike waves, polyspike waves, or rapid diffuse rhythms. Simultaneous video/EEG recording can help differentiate these seizure types. In most patients, these 3 types of seizures coexist.

The EEG during absence status epilepticus reveals continuous spike wave discharges, usually at a lower frequency than at baseline, and rapid rhythms during tonic status epilepticus.

Previous
Next

Neuroimaging Studies

In general, a magnetic resonance imaging (MRI) scan is the preferred neuroimaging study for a patient with LGS, rather than a CT scan. CT scans may be preferred in selected situations (eg, evaluation of suspected intracranial injury and/or hematoma in a patient with head trauma resulting from a seizure).

Abnormalities revealed by neuroimaging associated with LGS include tuberous sclerosis, brain malformations (eg, cortical dysplasias), hypoxia-ischemia injury, or frontal lobe lesions.

No current indication exists for routine positron emission tomography (PET) or single-photon emission computed tomography (SPECT) scanning in patients with LGS. However, PET or SPECT scans may be useful in patients undergoing evaluation as candidates for epilepsy surgery.

Previous
 
 
Contributor Information and Disclosures
Author

Koshi A Cherian, MD  Assistant Professor, Department of Neurology and Pediatrics, Albert Einstein College of Medicine; Attending Physician, Department of Neurology, Division of Child Neurology and Epilepsy, Montefiore Medical Center; Attending Physician, Department of Pediatrics, Division of Child Neurology, Jacobi Medical Center; Staff Physician (Courtesy), Department of Pediatrics, Division of Child Neurology, St Barnabas Hospital

Koshi A Cherian, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, American Medical Association, Child Neurology Society, and Medical Society of the State of New York

Disclosure: Nothing to disclose.

Coauthor(s)

Tracy A Glauser, MD  Professor, Departments of Pediatrics and Neurology, University of Cincinnati College of Medicine; Director, Comprehensive Epilepsy Center, Co-Director, Genetic Pharmacology Service, Cincinnati Children's Hospital Medical Center

Tracy A Glauser, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society

Disclosure: Eisai Consulting fee Consulting; Eisai Honoraria Speaking and teaching; Lundbeck Honoraria DSMB member; Questcor None Stock; Ortho McNeil Pharmaceutical Consulting fee Consulting; ucb Pharma Consulting fee Consulting; ucb Pharma Speaking and teaching

Diego A Morita, MD  Assistant Professor of Pediatrics and Neurology, Department of Pediatrics, Division of Neurology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine

Diego A Morita, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and American Medical Association

Disclosure: Nothing to disclose.

Karen Mary Stannard, MD, FRCPC  Fellow in Pediatric Epilepsy, Cincinnati Children's Medical Center

Karen Mary Stannard, MD, FRCPC is a member of the following medical societies: American Academy of Neurology, Child Neurology Society, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD  Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society

Disclosure: Nothing to disclose.

Additional Contributors

David A Griesemer, MD Professor, Departments of Neuroscience and Pediatrics, Medical University of South Carolina

David A Griesemer, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Neurology, American Epilepsy Society, Child Neurology Society, and Society for Neuroscience

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia. Dec 1997;38(12):1283-8. [Medline].

  2. Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. Jan 2009;8(1):82-93. [Medline]. [Full Text].

  3. Engel J Jr; International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. Jun 2001;42(6):796-803. [Medline].

  4. Heiskala H. Community-based study of Lennox-Gastaut syndrome. Epilepsia. May 1997;38(5):526-31. [Medline].

  5. Oguni H, Hayashi K, Osawa M. Long-term prognosis of Lennox-Gastaut syndrome. Epilepsia. 1996;37 Suppl 3:44-7. [Medline].

  6. Ohtsuka Y, Amano R, Mizukawa M, Ohtahara S. Long-term prognosis of the Lennox-Gastaut syndrome. Jpn J Psychiatry Neurol. Jun 1990;44(2):257-64. [Medline].

  7. Bare MA, Glauser TA, Strawsburg RH. Need for electroencephalogram video confirmation of atypical absence seizures in children with Lennox-Gastaut syndrome. J Child Neurol. Oct 1998;13(10):498-500. [Medline].

  8. van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. Dec 2008;4(6):1001-19. [Medline]. [Full Text].

  9. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. Dec 2007;9(4):353-412. [Medline].

  10. Conry JA, Ng YT, Paolicchi JM, Kernitsky L, Mitchell WG, Ritter FJ, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. May 2009;50(5):1158-66. [Medline].

  11. Ng YT, Collins SD. Clobazam. Neurotherapeutics. Jan 2007;4(1):138-44. [Medline].

  12. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. Oct 11 2011;77(15):1473-1481. [Medline].

  13. Feucht M, Brantner-Inthaler S. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia. Sep-Oct 1994;35(5):993-8. [Medline].

  14. You SJ, Kang HC, Kim HD, Lee HS, Ko TS. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev. Apr 2008;30(4):287-90. [Medline].

  15. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. Dec 18 1997;337(25):1807-12. [Medline].

  16. Glauser TA. Topiramate. Epilepsia. 1999;40 Suppl 5:S71-80. [Medline].

  17. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia. 2000;41 Suppl 1:S86-90. [Medline].

  18. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. Jun 10 1999;52(9):1882-7. [Medline].

  19. Pellock JM. Felbamate. Epilepsia. 1999;40 Suppl 5:S57-62. [Medline].

  20. [Best Evidence] Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. May 20 2008;70(21):1950-8. [Medline].

  21. Kluger G, Kurlemann G, Haberlandt E, Ernst JP, Runge U, Schneider F, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. Mar 2009;14(3):491-5. [Medline].

  22. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. Jul 2008;49(7):1123-41. [Medline].

  23. Ferrie CD, Patel A. Treatment of Lennox-Gastaut Syndrome (LGS). Eur J Paediatr Neurol. Nov 2009;13(6):493-504. [Medline].

  24. Lerner JT, Salamon N, Sankar R. Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms. Neuropsychiatr Dis Treat. Nov 8 2010;6:731-40. [Medline]. [Full Text].

  25. Cukiert A, Burattini JA, Mariani PP, Câmara RB, Seda L, Baldauf CM, et al. Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox-Gastaut and Lennox-like syndromes. Epilepsia. Feb 2006;47(2):371-4. [Medline].

  26. Ben-Menachem E, Hellström K, Waldton C, Augustinsson LE. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. Neurology. Apr 12 1999;52(6):1265-7. [Medline].

  27. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. Jun 2008;7(6):500-6. [Medline].

  28. Freeman JM, Vining EP, Kossoff EH, Pyzik PL, Ye X, Goodman SN. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia. Feb 2009;50(2):322-5. [Medline].

  29. De Los Reyes EC, Sharp GB, Williams JP, Hale SE. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol. Apr 2004;30(4):254-6. [Medline].

Previous
Next
 
Patient with Lennox-Gastaut syndrome wearing a helmet with face guard to protect against facial injury from atonic seizures
Slow spike wave pattern in a 24-year-old awake male with Lennox-Gastaut syndrome. The slow posterior background rhythm has frequent periods of 2- to 2.5-Hz discharges, maximal in the bifrontocentral areas, occurring in trains as long as 8 seconds without any clinical accompaniment.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.